Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTX-330 in advanced solid tumors and lymphoma
NCT05678998Phase 1Completed
- Sponsor
- Werewolf Therapeutics, Inc.
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of WTX-330 in solid tumor and non-Hodgkin lymphoma (NHL) (3 arms), sponsored by Werewolf Therapeutics, Inc. Primary endpoints: Dose Limiting Toxicities at 4 weeks, Treatment Emergent Adverse Events at 24 months and 2 more. Started Dec 2022; status: completed.
02
Drugs
WTX-330
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05678998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678998.